Skip to main content
. 2023 Jan 5;11(1):e02376-22. doi: 10.1128/spectrum.02376-22

FIG 7.

FIG 7

Analysis of the longevity of the anti-S1/S2 antibodies generated and the neutralizing capacity of the anti-RBD antibodies among the different vaccines. (A) Average anti-S1/S2 antibodies in participants without COVID-19 prior to vaccination. (B) Average anti-S1/S2 antibodies in participants with COVID-19 prior to vaccination. (C) Average inhibition rate of antibodies against the RBD in participants without COVID-19 prior to vaccination. (D) Average inhibition rate of anti-RBD antibodies in participants with COVID-19 prior to vaccination. The upper bars of each graph represent the periods of administration of the second dose. The confidence intervals of the percentages mentioned for this analysis are found in Table S1 in the supplemental material.